SCHEMBL9909273

SCHEMBL9909273

COC(=O)c1ccc2ncc(Cl)c(-c3ccc(OC)cc3Cl)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 1/20 0.44
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CSNK2A1 P68400 1/20 0.39
TP53 P04637 2/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
PAX8 Q06710 1/20 0.39
HPGDS O60760 1/20 0.39
SCN9A Q15858 1/20 0.39
NEK1 Q96PY6 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
THRB P10828 1/20 0.38
ALDH1A1 P00352 1/20 0.38
F2 P00734 1/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909256 0.90 HTR5A (0.54) HTR5ACA1CA2CSNK2A1TP53
SCHEMBL9909184 0.90 HTR5A (0.45) HTR5ACA1CA2HTTALDH1A1
SCHEMBL9907600 0.87 HTR5A (0.45) HTR5ACSNK2A1TP53ALOX15HTT
SCHEMBL9909182 0.86 CA1 (0.47) CA1CA2CSNK2A1ALOX15HTT
SCHEMBL9907565 0.85 TP53 (0.47) HTR5ACSNK2A1TP53ALOX15HTT
SCHEMBL9909246 0.84 HTR5A (0.66) HTR5AHPGDS
SCHEMBL9909230 0.83 MEN1 (0.44) HTR5ATP53ALOX15SCN9AMAPT
SCHEMBL9907559 0.82 HTR5A (0.44) HTR5ACSNK2A1TP53ALOX15HTT
SCHEMBL9103249 0.81 HTR5A (0.67) HTR5ACSNK2A1HTTMAPTSMN1; SMN2
SCHEMBL9909276 0.81 HTR5A (0.43) HTR5ACA1CA2CSNK2A1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885CA1 3584/4885CA2 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.